脑脊液中IL-17A表达与交通性脑积水患者临床预后的分析

doi:10.3969/j.issn.1009-976X.2024.06.007

摘要/Abstract

摘要： 目的本研究旨在探讨交通性脑积水患者术前脑脊液中白介素17A（IL-17A）水平对其临床预后的预测价值。方法回顾性分析2019年1月至2023年12月期间福建中医药大学附属第二人民医院神经外科收治的54例交通性脑积水患者的临床数据。所有入选患者均于术前接受了腰椎穿刺以收集脑脊液样本,检测脑脊液中的IL-17A水平。分别在术后4周和术后3年采用美国国立卫生研究院卒中量表（NIHSS）对患者的临床疗效进行评估,进而分析脑脊液IL-17A水平与临床疗效之间的潜在关系。结果研究数据显示,术前症状较为严重的患者脑脊液中IL-17A的表达水平较高。在术后4周的疗效评估中,我们发现90.7%的患者症状得到了显著改善,但脑脊液IL-17A的表达水平与术后即刻疗效之间的关联性并不显著。然而,在术后3年的长期疗效评估中,结果显示患者的NIHSS评分显著低于术前水平,且治疗疗效较好的患者脑脊液中IL-17A水平明显低于疗效较差的患者（P<0.05）。此外,出现不良反应的患者的脑脊液IL-17A的表达显著高于未出现不良反应的患者。结论本研究表明,脑脊液中IL-17A的表达水平可作为预测交通性脑积水患者临床长期预后的一个有效指标。这一发现为交通性脑积水的临床治疗提供了新的视角和潜在的干预靶点。

关键词: 白介素17A, 交通性脑积水, 临床疗效

Abstract: Objective This study aimed to explore the predictive value of preoperative cerebrospinal fluid （CSF） interleukin-17a （IL-17A） levels for the clinical prognosis of patients with communicating hydrocephalus. Methods This study retrospectively analyzed the clinical data of 54 patients with communicating hydrocephalus admitted to the Department of Neurosurgery of the Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine from January 2019 to December 2023. All selected patients underwent lumbar puncture before surgery to collect CSF samples for IL-17A level detection. The clinical efficacy of the patients was evaluated using the National Institutes of Health Stroke Scale （NIHSS） at 4 weeks and 3 years after surgery, and the potential relationship between CSF IL-17A levels and clinical efficacy was analyzed. Results The study data showed that patients with more severe preoperative symptoms had higher IL-17A expression levels in CSF. In the efficacy assessment at 4 weeks after surgery, 90.7% of the patients showed significant improvement in symptoms, but the association between CSF IL-17A levels and immediate postoperative efficacy was not significant. However, in the long-term efficacy assessment at 3 years after surgery, the NIHSS scores of the patients were significantly lower than those before surgery, and the CSF IL-17A levels of patients with better treatment efficacy were significantly lower than those with poorer efficacy （P < 0.05）. Additionally, the study indicated that patients with adverse reactions had significantly higher IL-17A expression levels in CSF than those without adverse reactions. Conclusion This study demonstrated that the expression level of IL-17A in CSF can serve as an effective indicator for predicting the long-term clinical prognosis of patients with communicating hydrocephalus. This finding provides a new perspective and potential intervention target for the clinical treatment of communicating hydrocephalus.

Key words: Interleukin-17A, communicating hydrocephalus, clinical efficacy

中图分类号:

R651.1

林海, 叶忠兴, 林玲, 胡瑜玲, 王蕊, 张文静, 唐文龙. 脑脊液中IL-17A表达与交通性脑积水患者临床预后的分析[J]. 岭南现代临床外科, 2025, 24(06): 378-383.

LIN Hai, YE Zhong-xing, LIN Ling, HU Yu-ling, WANG Rui, ZHANG Wen-jing, TANG Wen-long. IL-17A as a potential prognostic biomarker in communicating hydrocephalus patients[J]. Lingnan Modern Clinics In Surgery, 2025, 24(06): 378-383.

参考文献

[1] Kahle KT, Klinge PM, Koschnitzky JE, et al.Paediatric hydrocephalus[J]. Nat Rev Dis Primers, 2024, 10(1): 35.
[2] Carswell C.Idiopathic normal pressure hydrocephalus: historical context and a contemporary guide[J]. Pract Neurol, 2023, 23(1): 15-22.
[3] Ho YJ, Chiang WC, Huang HY, et al.Effectiveness and safety of ventriculoperitoneal shunt versus lumboperitoneal shunt for communicating hydrocephalus: A systematic review and meta-analysis with trial sequential analysis[J]. CNS Neurosci Ther, 2023, 29(3): 804-815.
[4] Karimy JK, Reeves BC, Damisah E, et al.Inflammation in acquired hydrocephalus: pathogenic mechanisms and therapeutic targets[J]. Nat Rev Neurol, 2020, 16(5): 285-296.
[5] Wang Q, Cheng J, Liu F, et al.Modulation of Cerebrospinal Fluid Dysregulation via a SPAK and OSR1 Targeted Framework Nucleic Acid in Hydrocephalus[J]. Adv Sci (Weinh), 2024, 11(17): e2306622.
[6] Braun M, Boström G, Ingelsson M, et al.Levels of inflammatory cytokines MCP-1, CCL4, and PD-L1 in CSF differentiate idiopathic normal pressure hydrocephalus from neurodegenerative diseases[J]. Fluids Barriers CNS, 2023, 20(1): 72.
[7] Kumar R, Theiss AL, Venuprasad K.RORγt protein modifications and IL-17-mediated inflammation[J]. Trends Immunol, 2021, 42(11): 1037-1050.
[8] Kogut MH, Lee A, Santin E.Microbiome and pathogen interaction with the immune system[J]. Poult Sci, 2020, 99(4): 1906-1913.
[9] Zhao J, Weng X, Bagchi S, et al.Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response[J]. Proc Natl Acad Sci USA, 2014, 111(7): 2674-9.
[10] Liu M, Wu K, Lin J, et al.Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease?[J]. Front Pharmacol, 2021, 12: 695957.
[11] Navarro-Compán V, Puig L, Vidal S, et al.The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases[J]. Front Immunol, 2023, 14: 1191782.
[12] Isailovic N, Daigo K, Mantovani A, et al.Interleukin-17 and innate immunity in infections and chronic inflammation[J]. J Autoimmun, 2015, 60: 1-11.
[13] Dai Q, Han S, Liu T, et al.IL-17A Neutralization Improves the Neurological Outcome of Mice With Ischemic Stroke and Inhibits Caspase-12-Dependent Apoptosis[J]. Front Aging Neurosci, 2020, 12: 274.
[14] Hu Y, Zheng Y, Wu Y, Ni B, Shi S.Imbalance between IL-17A-producing cells and regulatory T cells during ischemic stroke[J]. Mediators Inflamm, 2014, 2014:813045.
[15] Cao Y, Yu Y, Xue B, et al.IL (Interleukin)-17A Acts in the Brain to Drive Neuroinflammation, Sympathetic Activation, and Hypertension[J]. Hypertension, 2021, 78(5): 1450-1462.
[16] Piepke M, Clausen BH, Ludewig P, et al.Interleukin-10 improves stroke outcome by controlling the detrimental Interleukin-17A response[J]. J Neuroinflammation, 2021, 18(1): 265.
[17] Gelderblom M, Weymar A, Bernreuther C, et al.Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke[J]. Blood, 2012, 120(18): 3793-802.
[18] Levraut M, Bourg V, Capet N, et al.Cerebrospinal Fluid IL-17A Could Predict Acute Disease Severity in Non-NMDA-Receptor Autoimmune Encephalitis[J]. Front Immunol, 2021, 12: 673021.
[19] Huppert J, Closhen D, Croxford A, et al.Cellular mechanisms of IL-17-induced blood-brain barrier disruption[J]. FASEB J, 2010, 24(4): 1023-1034.